Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization

Llovet, 2003, Hepatocellular carcinoma, Lancet, 362, 1907, 10.1016/S0140-6736(03)14964-1 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Llovet, 2008, Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, 100, 698, 10.1093/jnci/djn134 Pang, 2006, Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma, Cancer Lett, 242, 151, 10.1016/j.canlet.2006.01.008 Tanaka, 2009, Molecularly targeted therapy for hepatocellular carcinoma, Cancer Sci, 100, 1, 10.1111/j.1349-7006.2008.01006.x Ribatti, 2006, Angiogenesis and anti-angiogenesis in hepatocellular carcinoma, Cancer Treat Rev, 32, 437, 10.1016/j.ctrv.2006.06.002 Marelli, 2007, Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies, Cardiovasc Intervent Radiol, 30, 6, 10.1007/s00270-006-0062-3 Suzuki, 2008, Radiologic measurements of tumor response to treatment: practical approaches and limitations, Radiographics, 28, 329, 10.1148/rg.282075068 Wahl, 2009, To PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, 50, 122S, 10.2967/jnumed.108.057307 Rudin, 2005, PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo, NMR Biomed, 18, 308, 10.1002/nbm.961 Young, 2009, Monitoring of tumor promotion and progression in a mouse model of inflammation-induced colon cancer with magnetic resonance colonography, Neoplasia, 11, 237, 10.1593/neo.81326 Jackson, 2003, Imaging microvascular structure with contrast enhanced MRI, Br J Radiol, 76, S159, 10.1259/bjr/22322389 Leach, 2005, The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations, Br J Cancer, 92, 1599, 10.1038/sj.bjc.6602550 Liang, 2007, Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: a preliminary result, Liver Int, 27, 516, 10.1111/j.1478-3231.2007.01456.x Taouli, 2010, Diffusion-weighted MR imaging of the liver, Radiology, 254, 47, 10.1148/radiol.09090021 Koh, 2007, Diffusion-weighted MRI in the body: applications and challenges in oncology, AJR Am J Roentgenol, 188, 1622, 10.2214/AJR.06.1403 Padhani, 2009, Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations, Neoplasia, 11, 102, 10.1593/neo.81328 Steingoetter, 2011, Reference region-based pharmacokinetic modeling in quantitative dynamic contract-enhanced MRI allows robust treatment monitoring in a rat liver tumor model despite cardiovascular changes, Magn Reson Med, 65, 229, 10.1002/mrm.22589 Vogl, 2007, Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results, Rofo, 179, 1113, 10.1055/s-2007-963285 Shinozaki, 2004, Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus, Mol Ther, 9, 368, 10.1016/j.ymthe.2003.12.004 Winkelmann, 2007, An optimal radial profile order based on the Golden Ratio for time-resolved MRI, IEEE Trans Med Imaging, 26, 68, 10.1109/TMI.2006.885337 Yankeelov, 2007, Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data, Magn Reson Med, 57, 353, 10.1002/mrm.21131 Team RDC. R: A language and environment for statistical computing; 2010. <http://www.bibsonomy.org/bibtex/2b73bfa376907e90089cf7434f67bfd53/yevb0?layout=simplehtml>. Altomonte, 2008, Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats, Hepatology, 48, 1864, 10.1002/hep.22546 Khan, 2000, Positron emission tomography scanning in the evaluation of hepatocellular carcinoma, J Hepatol, 32, 792, 10.1016/S0168-8278(00)80248-2 Trojan, 1999, Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma, Am J Gastroenterol, 94, 3314, 10.1111/j.1572-0241.1999.01544.x Metz, 2010, Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism, J Nucl Med, 51, 1691, 10.2967/jnumed.110.077719 Galban, 2010, Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-d-glucose-positron emission tomography imaging biomarkers, Clin Cancer Res, 16, 1542, 10.1158/1078-0432.CCR-08-1812 Herrmann, 2010, Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI, Mol Imaging Biol Aref, 2008, Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates, Magn Reson Imaging, 26, 1279, 10.1016/j.mri.2008.02.015 Kiessling, 2005, Improved correlation of histological data with DCE MRI parameter maps by 3D reconstruction, reslicing and parameterization of the histological images, Eur Radiol, 15, 1079, 10.1007/s00330-005-2701-5 Thoeny, 2005, Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats, Radiology, 234, 756, 10.1148/radiol.2343031721 Thoeny, 2005, Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration, Neoplasia, 7, 779, 10.1593/neo.04748